(旧版)ED診療ガイドライン 2012年版

8 治療

1) Rosen RC. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am 2001; 28: 269- 278(総説
2) Kirby M. Erectile dysfunction-an introduction. In: Erectile dysfunction and vascular disease. Oxford, UK: Blackwell Publishing, 2003: 1-23(教科書
3) Levine SB, Agle D. The effectiveness of sex therapy for chronic secondary psychological impotence. J Sex Marital Ther 1978; 4: 235- 258(レベルIVb
4) Takefman J, Brender W. An analysis of the effectiveness of two components in the treatment of erectile dysfunction. Arch Sex Behav 1984; 13: 321-340(レベルII
5) NIH Consenses Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83- 90(総説
6) Hedon F. Anxiety and erectile dysfunction: a global approach to ED enhances results and quality of life. Int J Impot Res 2003; 15: S16-S19(レベルVI
7) Wylie KR. Treatment outcome of brief couple therapy in psychogenic male erectile disorder. Arch Sex Behav 1997; 26: 527- 545(レベルIVb
8) 阿部輝夫.逆説的心理療法[ノン・エレクト法].日本臨牀2002; 60(増刊号6): 246 - 250. (レベルIII
9) Melnick T, Soares BGO, Nasello AG. The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med 2008; 5: 2562- 2574(レベルI
10) Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the Female Experience of Men’s Attitudes to Life Events and Sexuality (FEMALES)study. J Sex Med 2005; 2: 675- 684(レベルIVb
11) Riley A. When treating erectile dysfunction, do not forget the partner. Int J Clin Pract 2008; 62: 6- 8 (レベルVI
12) Badran W, Moamen N, Fahmy I, El-Karaksy A, Abdel-Nasser TM, Ghanem H. Etiological factors of unconsummated marriage. Int J Impot Res 2006; 18: 458- 463(レベルIII
13) Shamloul R. Management of honeymoon impotence. J Sex Med 2006; 3: 361-366(レベルIII
14) Ghanem H, El-Dakhly M, Shamloul R. Alternate-day tadalafil in the management of honeymoon impotence. J Sex Med 2008; 5: 1451- 1454(レベルIII
15) 高波真佐治.新婚シンポテンス.三浦一陽,石井延久編.性機能障害.南山堂,1998: 249 - 254(教科書
16) 岩本晃明,柳瀬敏彦,高栄哲,堀江均,馬場克幸,並木幹夫,名和田新.日本人成人男子の 総テストステロン,遊離テストステロンの基準値の設定.日泌尿会誌2004; 95: 751-760. (レベルIVb
17) Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol 2005; 63: 381-394(メタアナリシス
18) Petak SM, Baskin HJ, Bergman DA, Dickey RA, Nankin HR. ACCE Clinical Practice Guidelines for the evaluation and treatment of hypogonadism in adult male patients. American Association of Clinical Endocrinologists and the American College of Endocrinology-1996. Endocr Pract 1996; 2: 439 - 453 (ガイドライン
19) Amano T, Imao T, Takemae K, Iwamoto T, Yamakawa K, Baba K, Nakanome M, Sugimori H, Tanaka T, Yoshida K, Katabami T, Tanaka M. Profile of serum testosterone levels after application of testosterone ointment(Glowmin)and its clinical efficacy in late-onset hypogonadism patients. J Sex Med 2008; 5: 1727-1736(レベルIII
20) Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 2001; 28: 309- 319(総説
21) Kawanishi Y, Kimura K, Nakanishi R, Kojima K, Numata A. Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int 2004; 94: 361-368(レベルIVb
22) Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002; 53(Suppl 1): 61S -65S(レベルV
23) Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate(Viagra®)in clinical populations: an update. Urology 2002; 60(Suppl 2B): 12- 27(総説
24) Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate(Viagra®). Urology 2002; 60(Suppl 2B): 67- 90(総説
25) 白井將文,塚本泰司,佐藤嘉一,堀田浩貴,加藤修爾,八竹直,金子茂男,水永光博,谷口 成実,藤岡知昭,萬谷嘉明,岡田耕市,永島弘登志,岩堀泰司,滝本至得,平方仁,阿部輝夫, 村井勝,丸茂健,岩本安彦,高橋良当,高坂哲,甲斐祥生,小野寺恭忠,佐々木春明,石井 延久,永尾光一,福井準之助,永田幹男,貫井文彦,石堂哲郎,岩本晃明,矢島通孝.勃起不 全に対する経口治療薬シルデナフィルの無作為化二重盲検プラセボ対照比較試験成績.西 日泌尿2000; 62: 373- 382(レベルI
26) Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, on behalf of the Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61(Suppl 4A): 8 -14(レベルII
27) Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil(Levitra)for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16: 470- 478(総説
28) Stief C, Porst H, Sáenz de Tejada I, Ulbrich E, Beneke M, for the Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58: 230- 239(総説
29) Nagao K, Ishii N, Kamidono S, Osada T and the Vardenafil(Levitra)Clinical Trial Group. Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. Int J Urol 2004; 11: 515- 524(レベルII
30) Ishii N, Nagao K, Fujikawa K, Tachibana T, Iwamoto Y, Kamidono S. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006; 13: 1066-1072(レベルIII
31) Porst H. IC351(tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14(Suppl 1): S57-S64(総説
32) Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-1336(総説
33) Kloner RA, Jackson G, Hutter AM, Mittleman MA, Chan M, Warner MR, Costigan TM, Vail GM. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006; 97: 1778-1784(総説
34) Nagao K, Kimoto Y, Marumo K, Tsujimura A, Vail GM, Watts S, Ishii N, Kamidono S. Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006; 68: 845- 851(レベルII
35) Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170: 2356- 2358(レベルV
36) Barada J. Salvage of“ sildenafil(Viagra)failures” benefits of patient and retreatment with sildenafil. Int J Impot Res 2001; 13(Suppl 4): S49-S50(レベルV
37) McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate(Viagra®)in patients with erectile dysfunction. Urology 2002; 60(Suppl 2B): 28- 38(レベルV
38) Jiann BP, Yu CC, Su CC, Huang JK. Rechallenge prior sildenafil nonresponders. Int J Impot Res 2004; 16: 64-68(レベルV
39) Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, Ioannidis E. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005; 47: 518- 522(レベルV
40) Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for “non-responders” to tadalafil and vardenafil: a real-life study. Eur Urol 2006; 50: 126-133 (レベルV
41) Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804- 814(ガイドライン
42) Sur RL, Kane CJ. Sildenafil citrate-associated priapism. Urology 2000; 55: 950 xvii-950 xviii(レベルV
43) King SH, Hallock M, Strote J, Wessells H. Tadalafil-associated priapism. Urology 2005; 66: 432. e15- 432. e18(レベルV
44) Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM. Use of sildenafil (Viagra)in patients with cardiovascular disease. Circulation 1999; 99: 168-177(レベルI
45) Müller A, Shelton J, Parker M, Guhring P, Mulhall JP. Nitrate cessation profiles in men wishing to use sildenafil citrate. Urology 2007; 69: 946- 949(レベルIVb
46) Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality? J Sex Med 2005; 2: 751-758(総説
47) Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123: 103-107(レベルIVa
48) 独立行政法人医薬品医療機器総合機構.副作用が疑われる症例報告に関する情報. http://www.info.pmda.go.jp/fsearch/jsp/menu_fukusayou_base.jsp
49) Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E. Viagra deafness-sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope 2011; 121: 1049-1054(総説
50) Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology. Laryngoscope 2009; 119: 1586-1589(総説
51) Jackson G, Arver S, Banks I, Stecher VJ. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. Int J Clin Pract 2010; 64: 497- 504(レベルV
52) Chaubey SK, Sangla KS, Suthaharan EN, Tan YM. Severe hypoglycaemia associated with ingesting counterfeit medication. Med J Aust 2010; 192: 716- 717(レベルV
53) 佐々木春明,永尾光一,石井延久,杉田稔,丸茂健.インターネットを介した偽造ED医薬品4 社合同調査.日性会誌2010; 25: 19- 28(レベルV
54) Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001; 28: 335- 341(レベルI
55) Dutta TC, Eid JF. Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 1999; 54: 891-893(レベルV
56) Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol 1993; 149: 290- 294(レベルV
57) 小谷俊一,甲斐司光,成島雅博.陰圧式勃起補助用具によるインポテンス治療の経験. Impotence 1993; 8: 37- 42(レベルV
58) Canguven O, Bailen J, Fredriksson W, Bock D, Burnett AL. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med 2009; 6: 2561-2567(レベルV
59) Zippe CD, Pahlajani G. Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy. Urol Clin North Am 2007; 34: 601-618(レベルI
60) Linet OI, Ogrinc FG for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873- 877(レベルIII
61) Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802- 815(レベルI
62) Heaton JPW, Lording D, Liu S-N, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13: 317- 321(レベルI
63) 川西泰夫,木村和哲,新谷晃理,布川朋也,中西良一,山中正人,小島圭二,沼田明.勃起障 害の治療方法患者による評価と海綿体注射療法の意義.日性会誌2003; 18: 231-237(レベルV
64) 佐々木春明,七条武志,椎木一彦,青木慶一郎,鈴木俊一,島田誠,佐藤雅道,後藤隆太, 太田道也,池内隆夫,松田信泰,吉田英機.われわれの施設におけるPGE1 ICI テストの現状. 日性会誌2003; 18: 225- 229(レベルV
65) 小谷俊一,伊藤裕一.脊髄損傷者に対するPGE1 ICI テストと自己注射(当科での経験).日 性会誌2003; 18: 253- 260 (レベルV
66) 佐藤嘉一,丹田均,加藤修爾,大西茂樹,中嶋久雄,南部明民,新田俊一,小六幹夫,赤樫 圭吾,半澤辰夫,加藤隆一,久末伸一,鈴木一弘.三樹会病院におけるPGE1 ICI test とIC 自 己注射療法- sildenafil 無効および禁忌症例に対する検討- .日性会誌2003; 18: 219- 224. (レベルV
67) Nagai A, Kusumi N, Tsuboi H, Ishii K, Saika T, Nasu Y, Kumon H. Intracavernous injection of prostaglandin E1 is effective in patients with erectile dysfunction not responding to phosphodiseterase 5 inhibitors. Acta Medica Okayama 2005; 59: 279- 280(レベルV
68) Montorsi F, Basson R, Adaikan G, Becher E, Clayton A, Giuliano F, Khoury S, Sharlip I eds. Sexual medicine: sexual dysfunctions in men and women. Edition 2010. Paris: Editions 21, 2010(ガイドライン
69) Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol 1990; 143: 1138-1141(レベルI
70) 佐々木春明,荒木徹,牛山武久,小谷俊一,川西泰夫,木元康介,公文裕己,佐藤嘉一,白井 将文,武井実根雄,永井敦,永尾光一,堀田浩貴,丸茂健,安本亮二,吉田英機,日本性機能 学会自己注射認可推進委員会.ICI テスト副作用調査報告.日性会誌2003; 18: 277-282(レベルV
71) Kattan S. Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence. Urology 1995; 45: 1032-1036(レベルI
72) Moriel EZ, Rajfer J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol 1993; 149: 1299-1300(レベルV
73) Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001; 13: 326- 328(レベルIVa
74) Wilson SK, Delk JR II. Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol 1995; 153: 659- 661(レベルIVa
75) Carson CC III. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol 2004; 171: 1611-1614(レベルIVa
76) Dhar NB, Angermeier KW, Montague DK. Long-term mechanical reliability of AMS 700CX™/CXM inflatable penile prosthesis. J Urol 2006; 176: 2599- 2601(レベルIVa
77) Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007; 4: 1074-1079(レベルIVa
78) Natali A, Olianas R, Fisch M. Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med 2008; 5: 1503-1512(レベルIVa